Single Institutional Experience of Bladder-Preserving Trimodality Treatment for Muscle-Invasive Bladder Cancer

다국어 초록 (Multilingual Abstract)

The authors designed this study to determine the clinical effectiveness of trimodality

treatment, i.e., transurethral resection of a bladder tumor (TURBT) and concurrent

chemoradiotherapy (CRT). Twenty patients with a muscle-invasive bladder cancer

were treated by TURBT followed by concurrent cisplatin (75 mg/m2 day), administered

on weeks 1 and 4 of radiotherapy. According to residual tumor status after

TURBT, patients were classified into patients with a complete TURBT group and

incomplete TURBT group. Response to treatment was evaluated by restaging

TURBT at 4 weeks after completing CRT (post-CRT). Fifteen patients (75%) achieved

complete remission (CR) at restaging; 10 patients (50%) remained continuously

free of tumor recurrence. Disease-specific and overall survivals were 51.1% and

38.6% at 5 yr post-CRT, respectively. Of 16 patients in the complete TURBT group,

14 patients (87.5%) achieved CR, which was significantly different from that observed

in the incomplete TURBT group, in which only 1 (25%) of 4 patients achieved CR

(p=0.032). Five- year disease-specific and overall survivals were 71.6% and 53.5%,

respectively. Ten patients (90.9%) maintained their own bladder among the 11

surviving patients. Trimodality treatment was found to be an effective treatment in

patients who underwent complete TURBT for a muscle-invasive bladder cancer.

참고문헌 (Reference)

1 Rodel C, "Trimodality treatment and selective organ preservation for bladder cancer" 24 : 5536-5544, 2006

2 Shipley WU, "Treatment of invasive bladder cancer by cisplatin and radiation in patients unsuited for surgery" 258 : 931-935, 1987

3 Gospodarowicz MK, "The role of radiation therapy in the management of transitional cell carcinoma of the bladder" 6 : 147-168, 1992

4 Kaufman DS, "The initial results in muscle-invading bladder cancer of RTOG 95-06: phase I/II trial of transurethral surgery plus radiation therapy with concurrent cisplatin and 5-fluorouracil followed by selective bladder preservation or cystectomy depending on the initial response" 5 : 471-476, 2000

5 Sauer R, "Radiotherapy with and without cisplatin in bladder cancer" 19 : 687-691, 1990

6 Weiss C, "Radiochemotherapy with cisplatin and 5-fluorouracil after transurethral surgery in patients with bladder cancer" 68 : 1072-1080, 2007

7 Nichols RC Jr, "Radiation therapy and concomitant palcitaxel/carboplatin chemotherapy for muscle invasive transitional cell carcinoma of the bladder: a well tolerated condition" 90 : 281-286, 2000

8 Hagan MP, "RTOG 97-06:Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy" 57 : 665-672, 2003

9 Osen I, "Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study" 81 : 862-869, 1998

10 Sangar VK, "Phase I study of conformal radiotherapy with concurrent gemcitabine in locally advanced bladder cancer" 61 : 420-425, 2005

11 Dunst J, "Organ-sparing treatment in muscle-invasive bladder cancer" 181 : 632-637, 2005

12 Bajorin DF, "Long term survival in metastatic transitional cell carcinoma and prognostic factors predicting outcome of therapy" 17 : 3173-3181, 1999

13 Shipley WU, "Lane SC, Thakral HK, Althausen AF, Zietman AL. Selective bladder preservation by combined modality protocol treatment: Long-term outcomes of 190 patients with invasive bladder cancer" 60 : 62-68, 2002

14 Cohen-Jonathan E, "Farnesyltransferase inhibitors potentiate the antitumor effect of radiation on a human tumor xenograft expressing activated HRAS" 154 : 125-132, 2000

15 Chakravarti A, "Expression of the epidermal growth factor receptor and Her-2 are predictors of favorable outcome and reduced complete response rates, respectively, in patients with muscle-invading bladder cancers treated by concurrent radiation and cisplatin-based chemotherapy: a report from the Radiation Therapy Oncology Group" 62 : 309-317, 2005

16 Dalbagni G, "Cystectomy for bladder cancer: a contemporary series" 165 : 1111-1116, 2001

17 Danesi DT, "Conservative treatment of invasive bladder carcinoma by transurethral resection, protracted intravenous infusion chemotherapy, and hyperfractionated radiotherapy: long term results" 101 : 2540-2548, 2004

18 Varveris H, "Concurrent platinum and docetaxel chemotherapy and external radical radiotherapy in patients with invasive transitional cell carcinoma: a preliminary report of tolerance and local control" 17 : 4771-4780, 1997

19 Rodel C, "Combined-modality treatment and selective organ preservation in invasive bladder cancer: Long-term results" 20 : 3061-3071, 2002

20 Housset M, "Combined radiation and chemotherapy for invasive transitional-cell carcinoma of the bladder; a prospective study" 11 : 2150-2157, 1993

21 Kachnic LA, "Bladder preservation by combined modality therapy for invasive bladder cancer" 15 : 1022-1029, 1997

22 Rodel C, "Apoptosis, p53, bcl-2, and Ki-67 in invasive bladder carcinoma: possible predictors for response to radiochemotherapy and successful bladder preservation" 46 : 1213-1221, 2000

23 Pollack A, "Abnormal bcl-2 and pRb expression are independent correlates of radiation response in muscle-invasive bladder cancer" 3 : 1823-1829, 1997

24 Zietman AL, "A phase I/II trial of transurethral surgery combined with concurrent cisplatin, 5-fluorouracil and twice daily radiation followed by selective bladder preservation in operable patients with muscle invading bladder cancer" 150 : 1673-1677, 1998